Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hard-to-treat myeloma: drug duo enters human trials

NCT ID NCT06896916

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs, etentamig and iberdomide, in adults with multiple myeloma that has returned or stopped responding to treatment. The goal is to find a safe dose and see if the combo can control the cancer. About 135 participants will take part at sites worldwide.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Mar 2036

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance of 0 or 1. * Must have confirmed diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) after the participant's last treatment, as outlined in the protocol. * All participants must have measurable diseases per central laboratory as outlined in protocol Exclusion Criteria: * Has received prior etentamig treatment. * Prior exposure to BCMA-targeted therapy as noted in the protocol. * Has received prior cereblon E3 ligase modulatory drug (CELMoD) (iberdomide or mezigdomide).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    27 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Amsterdam UMC, Location VUmc /ID# 267670

    RECRUITING

    Amsterdam, North Holland, 1081 HV, Netherlands

  • Austin Hospital /ID# 265984

    RECRUITING

    Melbourne, Victoria, 3084, Australia

  • Beverly Hills Cancer Center /ID# 266921

    RECRUITING

    Beverly Hills, California, 90211, United States

  • Blacktown Hospital /ID# 265983

    RECRUITING

    Blacktown, New South Wales, 2148, Australia

  • Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau /ID# 267694

    RECRUITING

    Tours, Indre-et-Loire, 37000, France

  • Chu De Lille - Hopital Claude Huriez /ID# 270193

    RECRUITING

    Lille, Hauts-de-France, 59037, France

  • Chu de Nice-Hopital Larchet Ii /Id# 266845

    RECRUITING

    Nice, Alpes-Maritimes, 06202, France

  • Colorado Blood Cancer Institute /ID# 273751

    RECRUITING

    Denver, Colorado, 80218, United States

  • Dokkyo Medical University Hospital /ID# 271648

    RECRUITING

    Mibu, Tochigi, 321-0293, Japan

  • Hôpital La Timone /ID# 267053

    RECRUITING

    Marseille, Bouches-du-Rhone, 13885, France

  • IUCT Oncopole /ID# 266391

    RECRUITING

    Toulouse, Occitanie, 31059, France

  • Jewish General Hospital /ID# 267574

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

  • Kumamoto University Hospital /ID# 270530

    RECRUITING

    Kumamoto, Kumamoto, 860-8556, Japan

  • Memorial Sloan Kettering Cancer Center - New York - York Avenue /ID# 270282

    RECRUITING

    New York, New York, 10065, United States

  • National Cancer Center Hospital East /ID# 268343

    RECRUITING

    Kashiwa-shi, Chiba, 277-8577, Japan

  • Nippon Medical School Hospital /ID# 270254

    RECRUITING

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Oslo Universitetssykehus Ulleval /ID# 275433

    RECRUITING

    Oslo, 0450, Norway

  • Rutgers Cancer Institute of New Jersey /ID# 266833

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • Sir Charles Gairdner Hospital /ID# 265985

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • Swedish Medical Center - Seattle /ID# 268052

    RECRUITING

    Seattle, Washington, 98104, United States

  • The Alfred Hospital /ID# 265981

    RECRUITING

    Melbourne, Victoria, 3004, Australia

  • The Cancer Institute Hospital Of JFCR /ID# 268342

    RECRUITING

    Koto-ku, Tokyo, 135-8550, Japan

  • Universitair Medisch Centrum Utrecht /ID# 267660

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • University Health Network_Princess Margaret Cancer Centre /ID# 275636

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • University Of North Carolina Health Care - Hillsborough Campus /ID# 278230

    RECRUITING

    Hillsborough, North Carolina, 27278, United States

  • Washington University /ID# 266972

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Wollongong Hospital /ID# 265625

    RECRUITING

    Wollongong, New South Wales, 2500, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.